Loader Background
Request a demo
Quantum Surgical SAS (Headquarters)
1000 rue du Mas de Verchant,
34000 Montpellier
FRANCE
Quantum Surgical Inc.
801 Brickell Avenue, Suite 809
Miami, FL 33131
USA
Press releases / Jul 2, 2024

New Study: American Public Largely Supportive of the Use of Surgical Robots in Cancer Treatment

  • 55% of American citizens express concern about younger generations being affected by cancer (compared to 37% of Germans).
  • 56% of American citizens believe that robotic or AI solutions could make cancer treatments more effective.
  • Looking ahead, only 7% of American citizens are familiar with percutaneous ablation (compared to 23% of French).

Montpellier, July 2nd 2024 – To better understand public apprehension towards cancer and their knowledge of treatments, the medical robotics company Quantum Surgical surveyed them. Conducted on both sides of the Atlantic, the YouGov study reveals that a majority of American and French citizens fear that future generations will suffer from cancer, unlike Germans. Additionally, over half of the American believe that robotic solutions can enhance cancer treatments. However, data also shows that percutaneous ablation, a minimally invasive technique significantly reducing recovery time, is still relatively unknown in the U.S.

Cancer: A Major Concern for a Majority of American People

While the WHO predicts a 77% increase in cancer cases worldwide by 2050 [1], 53% of Americans fear being diagnosed with cancer, a concern shared by the French (54%). Furthermore, over half of American people express concern for the young people close to them; the concern reaches nearly two-thirds in France. This contrasts significantly with Germany, where only 37% fear for their younger generations.

Even more surprising: 47% of Americans aged 18 to 24 express concerns about future generations, compared to 74% of young French.

Americains and French More Confident Than Germans in Robotics to Enhance Cancer Treatments

A majority of Americans and French perceive robotics as an effective solution to improve cancer treatments (56% and 53% respectively). This enthusiasm is particularly notable among American men (59% compared to 52% among women). Similar gender disparities exist in France where it reaches the significant disparity of 63% versus 44%.

In contrast, only 44% of German respondents believe that robotics is an effective solution to improve cancer treatments.

The WHO’s predictions suggest that cancer will unfortunately be a reality for many people. The fact that the majority of Americans believe that robotics and AI can make cancer treatments more effective is very encouraging. At Quantum Surgical, we have demonstrated with Epione® how technology can concretely assist practitioners in improving cancer treatment for patients,” said Bertin Nahum, President and Co-founder of Quantum Surgical.

Percutaneous Ablation: A Future Solution Little Known in the United States Compared to Other Countries

Only 7% of American respondents are familiar with percutaneous ablation as a cancer treatment method, a figure that rises to 11% among cancer patients. This percentage is significantly lower than the 23% of French who report knowing about this new form of therapy and is similar to Germans (6%).

In fact, percutaneous ablation is the least known cancer treatment among the Americans, in comparison to other therapies: 77% are familiar with chemotherapy, 68% with surgery, 59% with bone marrow transplant, 53% with radiotherapy, 35% with immunotherapy and 30% hormone therapy.

This technique, currently underrecognized and underutilized globally, offers numerous benefits. Bertin Naum, CEO et co-fondateur de Quantum Surgical, explains, “The challenge now is to democratize assisted percutaneous ablation, a minimally invasive technique that destroys cancerous tumors by inserting one or more needles through the skin. The patient benefits of these minimally invasive treatments are manifold: fewer complications and pain post-procedure, reduced scarring, shorter hospital stays, and faster recovery.

 Epione® is CE marked in Europe for abdominal and lung tumors, and FDA authorized for abdominal tumors. Epione® is available at the Miami Cancer Institute and Miami Cardiac & Vascular Institute, part of Baptist Health South Florida, and three hospitals in France.

 Alcohol Consumers Less Anxious… in France!

What about the respondent profiles? In the U.S., 57% and 58% of smokers and heavy alcohol consumers fear being diagnosed with cancer. This statistic drops at 45% in Germany for both categories. Surprisingly, in France, while 57% of smokers fear future cancer diagnosis, only 45% of heavy alcohol consumers share this concern. However, the link between alcohol consumption and cancer is clearly established. It is responsible for 7.1% of cancers in Europe [1] and approximately 6% of all cancers and 4% of all cancer deaths in the United States [2].

 Methodology

The Quantum Surgical study was conducted online from February 20 to 21, 2024 with over 4,000 respondents in France, Germany, and the United States.

About Quantum Surgical

Quantum Surgical is a French company specialized in medical robotics and AI, co-founded in 2017 by Bertin Nahum, CEO.

With a dynamic team of over 110 employees, the company is headquartered in Montpellier, France, and has offices in Miami, Florida. Its Epione® platform is dedicated to the curative and early treatment of cancers.

Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide.

Quantum Surgical was awarded the prestigious Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research, and joined in 2023 the governmental French Tech 2030 program in 2023 that supports top emerging actors in disruptive innovation.

For more information : www.quantumsurgical.com

Press Contact Quantum Surgical

Stéphanie Moy
s.moy@quantumsurgical.com
Tel. : +33 (0)6 32 55 85 48

Press contact